

CLAIMS

1. A preparation for continuous intravenous administration containing hepatocyte growth factor (HGF) as an active ingredient.

5 2. The preparation for continuous intravenous administration of claim 1, wherein the preparation is used in treatment or prevention of renal disease.

3. The preparation for continuous intravenous administration of claim 2, wherein the renal disease is acute renal failure or chronic renal failure.

4. The preparation for continuous intravenous administration of claim 1, wherein the preparation is used in treatment or prevention of occlusive lesion of blood vessel.

5. The preparation for continuous intravenous administration of claim 4, wherein the occlusive lesion of blood vessel includes lower limb ischemia, acute arterial occlusion, chronic arterial occlusion, arteriosclerosis obliterans, arterial embolism, arterial thrombosis, Buerger's disease, venous occlusion, venous thrombosis, thrombotic phlebitis, angiodysplasia, vascular damage, coronary occlusion, coronary stenosis, pulmonary embolism, and arterial occlusion of organs.

6. A method for treating or preventing renal disease which comprises administering an effective amount of HGF by continuous intravenous administration.

7. A method for treating or preventing occlusive lesion of blood vessel which comprises administering an effective amount of HGF by continuous intravenous administration.